A large cohort of 29,908 patients with pathologic stage T2N0M0 NSCLC showed improved median overall survival and 5-year OS when receiving adjuvant chemotherapy. The study demonstrated a benefit from adjuvant chemotherapy in patients with completely resected stage T2N0M0 NSCLC regardless of tumor size.
The International Association for the Study of Lung Cancer calls on Asian-Pacific governments to take action against lung cancer, citing the need for effective tobacco control, affordable healthcare, and early diagnosis. The goal is to reduce lung cancer deaths by one-third by 2030.
The IASLC consensus statement provides key pathologic, diagnostic, and therapeutic considerations for managing EGFR mutation positive NSCLC patients. It recommends optimal choice of EGFR TKIs, management of brain metastasis, and use of circulating free DNA for molecular studies.
The 2016 Asia Pacific Lung Cancer Conference presented the latest advances in lung cancer research, including immunotherapy and multidisciplinary practices. Tobacco use was also a major concern, with experts emphasizing the need for stricter control measures to reduce deaths from lung cancer in Southeast Asia.
Researchers evaluated an IHC screening tool for ROS1 gene rearrangements in a cohort of 170 patients. The results showed high sensitivity and specificity rates, making it a feasible option for first-line screening in a lung cancer setting.
A study compared four PD-L1 IHC diagnostic assays in lung cancer, demonstrating similarities and differences. The findings support the use of each assay according to its specific indication, recommending utilization for distinct scoring algorithms.
The International Association for the Study of Lung Cancer (IASLC) highlights significant progress in lung cancer prevention, diagnosis, staging, and treatment in 2015. The organization introduces a comprehensive educational resource covering topics such as tobacco control, early detection, and immunotherapy.
Researchers identified a novel mutation in the KIT gene that contributes to crizotinib resistance in ROS1+ non-small cell lung cancer patients. Ponatinib, a KIT tyrosine kinase inhibitor, demonstrates potential as a therapeutic option for overcoming this resistance.
CV screening workstations aid technicians in accurately reviewing LDCT scans, leading to reduced false positives and improved efficiency. The study found 97.8% sensitivity and 98% specificity in identifying abnormal scans, with average review time of 208 seconds.
A cross-sectional survey found that detailed clinician communication can alleviate patient distress associated with incidental pulmonary nodules. Patients who received accurate information about their nodule size and diagnosis had a more reassuring experience, reducing anxiety and improving overall well-being.
The ALCF-IASLC Joint Fellowship Award supports novel research with the potential to positively impact lung cancer patients. Dr. Robin Mjelle's project aims to develop a risk-prediction tool and serum poly-marker kit for early lung cancer detection, leveraging pre-diagnostic serum samples from Norway's HUNT biobank.
A new method using proton nuclear magnetic resonance (H-NMR) of blood plasma identifies unique metabolic biomarkers for early and late-stage lung cancer. The technique correctly classifies 78% of patients and 92% of controls, showing promise as a complementary tool to improve lung cancer screening.
A recent study published in Journal of Thoracic Oncology found that the FDA-approved VENTANA anti-ALK(D5F3)CDx assay is superior to the 5A4 IHC assay for selecting patients with non-small cell lung cancer eligible for ALK tyrosine kinase inhibitor treatment.
Researchers identified 5 autoantibody classifiers that can distinguish lung cancer from smoker controls with high sensitivity and specificity, as well as those from benign lung nodules. These findings have the potential to improve early detection of lung cancer through companion molecular diagnostic modalities.
Afinatinib has shown significant clinical benefits for NSCLC patients with brain metastases, including improved PFS (8.2 vs. 5.4 months) and ORR (73% vs. 25%) compared to standard platinum doublet chemotherapy. The drug's efficacy was particularly notable in patients harboring EGFR Del19 mutations.
Research published in Journal of Thoracic Oncology found that non-small cell lung cancer patients with early-stage tumors had a higher rate of nodal upstaging and longer hospital stays when undergoing open chest surgery compared to video-assisted thoracic surgery (VATS). This study suggests that VATS may not be equivalent to open surge...
A new study reveals that mandatory tumor tissue requirements in clinical trials delay treatment and reduce patient enrollment. Trials without these requirements show faster treatment initiation and higher enrollment rates.
A phase III trial showed that sorafenib modestly increased progression-free survival (PFS) and disease control rate in NSCLC patients, but did not impact overall survival. The study also found that EGFR mutation positive patients receiving sorafenib had significantly longer OS and PFS.
The International Association for the Study of Lung Cancer has released new data for the TNM classification of lung cancer, which will inform the Eighth Edition of the staging manual. The new database includes 94,708 patients diagnosed worldwide from 1999-2010 and analyzes tumor size, lymph node involvement, and metastatic status.
The new 2015 WHO Classification of Lung Tumors provides standard criteria for pathology diagnosis and clinical practice. The updated classification focuses on histologic subtyping and classification according to predominant subtype, leading to multiple new discoveries in lung adenocarcinoma.
The International Association for the Study of Lung Cancer (IASLC) has issued a new statement on tobacco control and smoking cessation, calling for increased taxes on tobacco products to reduce cigarette smoking. The organization also emphasizes comprehensive advertising and promotion bans and product regulation, including pack warnings.
The International Association for the Study of Lung Cancer (IASLC) has selected 5 advocates to attend the 16th World Conference on Lung Cancer, where they will share and learn strategies to increase awareness. The recipients include Hildreth Grossman, Kathleen Mewhiney, Victor Lasebikan, Seda Kansu, and Tetsuya Yamaoka.
Dr. Fred R. Hirsch, MD, PhD, is honored with the Addario Foundation Lectureship Award for his contributions to lung cancer research, education, and service. The award recognizes his dedication to eliminating lung cancer worldwide through translational-clinical research.
The study of over 160,000 postmenopausal women revealed no significant link between lung cancer risk and reproductive history or hormone therapy. However, some subgroups showed reduced risks for specific types of lung cancer, emphasizing the need for further research into complex relationships.
Physical activity has been shown to reduce symptoms, increase exercise tolerance, and improve quality of life in lung cancer patients. Additionally, increased physical activity may also benefit lung cancer survivors by improving exercise capacity and symptom burden.
Researchers found that patients with stage I non-small cell lung cancer (NSCLC) and low tumor metabolic activity have increased overall survival. A diagnostic test using fluorodeoxyglucose positron emission tomography (FDG/PET) can help identify patients who may benefit from post-surgical chemotherapy.
The study found a significant decline in early recall rates from 20% to 3-4% in subsequent rounds, while lung cancer detection rates decreased by 50%. A well-organized screening program with access to previous images and results is crucial to manage false positives.
Patients treated at high-volume facilities for stage III non-small cell lung cancer (NSCLC) have longer overall survival when receiving definitive concurrent chemotherapy and radiation therapy. Studies show improved outcomes for patients treated at these centers, regardless of academic or community status.
An interactive online education tool has been developed to help practicing oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) by providing feedback from an expert panel. The tool integrates clinical, histological, and molecular features into treatment plans, leading to a change in treatment cho...
Researchers found elevated levels of malignant mesothelioma cases in southern Nevada counties due to environmental exposure to carcinogenic mineral fibers. The incidence is higher in locations with known industrial exposure, with a male-to-female ratio of 2:1 in affected counties.
Researchers found that rare EGFR mutations in non-small cell lung cancer (NSCLC) have distinct impacts on disease outcome and therapy response. Classic EGFR mutations were associated with better overall survival and higher TKI therapy response rates compared to rare mutations, which were linked to tobacco smoking and poorer prognosis.
The NELSON trial found that individuals with better health profiles and younger age were less likely to participate, but the study's findings remain relevant due to modest differences. The trial showed a higher mortality rate among eligible non-participants compared to participants.
A study found that multiplexed genetic screening for EGFR and ALK gene rearrangements followed by molecularly-guided treatment is cost-effective compared to standard chemotherapy. The approach offers better outcomes in terms of quality-adjusted life years gained and life-years, making it a valuable option for patients with NSCLC.
Researchers used targeted NGS to identify genetic alterations in genes involved in DNA repair, cell survival, and proliferation pathways. The study found that accumulated mutations correlate with tumor progression and decreased survival rates in patients with advanced malignant lung cancer. The results highlight the potential of NGS to...
A nationwide survey of 2200 French adults reveals significant knowledge gaps about lung cancer, including misconceptions about screening, treatment options, and prognosis. The study emphasizes the need for public education to address these gaps and improve outcomes.
Researchers found that pretreatment interstitial lung disease significantly increases the risk of developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy. The study's results suggest that clinicians should be cautious when considering SBRT f...
A risk stratification model based on lymph node characteristics confirms the true lack of lung cancer in sampled nodes. The model categorizes low-risk nodes with a high chance of being truly negative, while high-risk nodes have a significant false-negative rate.
Low preoperative serum squamous cell carcinoma antigen levels and absence of tumor invasion into the pleura or blood vessels are independent prognostic factors for patients with peripheral squamous cell carcinomas of the lung. These factors are associated with longer overall survival and reduced disease recurrence.
A European multicenter harmonization study reveals that standardized semi-quantitative anaplastic lymphoma kinase (ALK) IHC is reliable and comparable to FISH testing for detecting ALK protein expression. The study showed 100% concordance among institutions on 15 well-characterized NSCLC specimens, making IHC a potential stand-alone test.
A novel software application, CANARY, can automatically analyze high-resolution CT images to classify early-stage non-small cell lung cancer patients into risk groups. The tool was developed at Mayo Clinic and demonstrated accurate stratification of patients into categories with different 5-year disease-free survival outcomes.
The NCI/FDA workshop resulted in the development of two innovative clinical trials, Lung-MAP and ALCHEMIST, which employ a 'Master Protocol' approach to improve patient outcomes. These trials aim to accelerate the development of targeted therapies for lung cancer by integrating multiple sub-studies based on genomic profiles.
Researchers found modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy, but no clinically significant cardiac events. The study suggests that longer follow-up and increased dose range may reveal the impact of radiation on late RT-related toxicity.
A new study found that high-risk individuals screened for early-stage lung cancer using low-dose computed tomography (LDCT) can reduce treatment costs by up to 85%, resulting in a significant reduction in mortality rates and improved patient outcomes. The average cost per-person for LDCT screening was $453, while the mean cost for diag...
Researchers found high concordance (94%) between EGFR mutations in plasma-derived ctDNA and tumor tissue in NSCLC patients. This suggests that a single plasma sample may be sufficient for mutation status assessment when tumor tissue is unavailable.
Researchers found BIM deletion independently predicts overall and progression-free survival in advanced NSCLC patients, particularly in those treated with EGFR TKIs or chemotherapy. The study suggests considering BIM deletion as a clinical trial stratification factor for Asian NSCLC patients.
Researchers identify RET M918T mutation in SCLC tumors, which drives increased ERK signaling and MYC expression. The mutation makes cells sensitive to tyrosine kinase inhibitors ponatinib and vandetanib.
ROS1 gene fusions were detected in 12 out of 492 specimens examined for lung adenocarcinoma using RT-PCR and IHC tests. ROS1 positive patients are significantly younger than the entire population, but there are no associations with gender or smoking history.
Increased use of less toxic chemotherapy treatments in advanced NSCLC is associated with higher overall survival. The study found a significant increase in survival rates among patients receiving second-line therapy, with median overall survival ranging from 3.9 to 11.8 months.
A recent study found that a 5-year low-dose computed tomography (LDCT) screening protocol can detect lung cancer effectively, with a high proportion of cancers being treated and good long-term survival rates. The results show improved diagnostic performance compared to other studies, including the National Lung Cancer Screening Trial.
A systematic review of 8215 studies found that low-dose computed tomography (LDCT) screening does not significantly influence overall quality of life or result in long-term anxiety or distress. However, positive results can lead to short-term increases in distress levels.